Connexion
Connexion
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Inscription
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BLUEPRINT MEDICINES CORPORATION

(BPMC)
  Rapport
Temps réel estimé Cboe BZX  -  19:51:03 06/02/2023
45.71 USD   +0.13%
23/01Blueprint Medicines obtient l'examen prioritaire de la FDA pour la demande supplémentaire de nouveau médicament Ayvakit
MT
23/01Blueprint Medicines Corporation : Barclays maintient son opinion neutre
ZM
23/01Blueprint Medicines Corporation annonce l'acceptation par la FDA de la demande supplémentaire de drogue nouvelle pour AYVAKIT(R)
CI
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur BLUEPRINT MEDICINES CORPORATION
24/01Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for A..
23/01Blueprint Medicines Gets FDA's Priority Review For Ayvakit Supplemental New Drug Applic..
23/01Blueprint Medicines Gets FDA Priority Review for Ayvakit in Indolent Systemic Mastocyto..
23/01Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for A..
23/01Blueprint Medicines Corporation Announces FDA Acceptance of Supplemental New Drug Appli..
17/01Taiwan Approves CStone Pharmaceuticals' New Drug Application for Lung, Thyroid Cancer T..
09/01Blueprint Medicines Corp : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
06/01Blueprint Medicines Corp : Change in Directors or Principal Officers, Financial Statements..
06/01Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors
06/01Blueprint Medicines Corporation Announces Board Changes
05/01Blueprint Medicines Expects to Hit High End of 2022 Revenue Target Range
04/01Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/01North American Morning Briefing: Futures Rise -2-
2022Blueprint Medicines Corp : Change in Directors or Principal Officers, Financial Statements..
2022Blueprint Medicines Corporation Reports Clinical Data Highlighting Leadership in Develo..
2022Insider Sell: Blueprint Medicines
2022Blueprint Medicines Corp : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year..
2022Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022Blueprint Medicines Submits Supplemental New Drug Application for Ayvakit to US FDA for..
2022Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (Avap..
2022Blueprint Medicines to Present at Upcoming Investor Conferences
2022Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022BLUEPRINT MEDICINES CORP Management's Discussion and Analysis of Financial Condition a..
2022Blueprint Medicines Posts Wider Q3 Loss, Revenue Rises
2022Blueprint Medicines : Q3 Earnings Snapshot
2022Blueprint Medicines Corp : Results of Operations and Financial Condition, Regulation FD Di..
2022Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q3 Revenue $66M
2022Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q3 Loss $-2.23
2022Blueprint Medicines Corporation Reports Earnings Results for the Third Quarter and Nine..
2022Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and ..
2022Blueprint Medicines Corporation Provides Revenue Guidance for 2022
2022Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Resu..
2022Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022Blueprint Medicines : Management Change/Compensation - Form 8-K
2022Blueprint Medicines Corp : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
2022Blueprint Medicines Corp : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
2022Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022Blueprint Medicines Demonstrates Systemic Mastocytosis' Symptoms; Shares Rise
2022CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Syste..
2022Blueprint Medicines Corporation Announces CANCER Publishes Study Demonstrating Substant..
2022Insider Sell: Blueprint Medicines
2022Insider Sell: Blueprint Medicines
2022Blueprint Medicines' Positive Topline Results in Ayvakit Trial Could Support Potential ..
2022Blueprint Medicines Reports Positive Top-line Results in Non-Advanced Systemic Mastocyt..
2022Sector Update: Health Care Stocks Slip Premarket Wednesday
2022Blueprint Medicines Corp : Other Events, Financial Statements and Exhibits (form 8-K)
2022Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® ..
2022Blueprint Medicines Announces Positive Top-Line Results from Pioneer Trial of AYVAKIT® ..
2022Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022BLUEPRINT MEDICINES CORP Management's Discussion and Analysis of Financial Condition a..
2022Blueprint Medicines Reports Wider Q2 Loss as Revenue Advances, Full-Year Sales Guidance..
2022Blueprint Medicines : Reports Second Quarter 2022 Results - Form 8-K
2022Blueprint Medicines : Q2 Earnings Snapshot
2022Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q2 Loss $-2.68
2022Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q2 Revenue $36.5M
2022Blueprint Medicines Reports Second Quarter 2022 Results
2022Blueprint Medicines Corporation Reports Earnings Results for the Second Quarter and Six..
2022Blueprint Medicines Corporation Provides Revenue Guidance for 2022
2022Blueprint Medicines Corporation announced that it has received $400 million in funding
2022Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August ..
2022Blueprint Medicines Publishes Inaugural Corporate Responsibility Report
2022Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022Blueprint Medicines Corp : Entry into a Material Definitive Agreement, Creation of a Direc..
2022Blueprint Medicines Secures $1.25 Billion Strategic Financing Via Partnerships with Roy..
2022Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to ..
2022Blueprint Medicines Corporation announced that it expects to receive $400 million in fu..
2022Blueprint Medicines Corp : Change in Directors or Principal Officers, Submission of Matter..
2022Blueprint Medicines Corporation(NasdaqGS:BPMC) drop..
2022Blueprint Medicines Corporation(NasdaqGS:BPMC) drop..
2022Blueprint Medicines Corporation(NasdaqGS:BPMC) drop..
2022Blueprint Medicines Corporation(NasdaqGS:BPMC) drop..
2022Blueprint Medicines Corporation(NasdaqGS:BPMC) drop..
2022Blueprint Medicines Corporation(NasdaqGS:BPMC) drop..
2022Blueprint Medicines Corporation(NasdaqGS:BPMC) drop..
2022Blueprint Medicines Corporation(NasdaqGS:BPMC) drop..
2022Blueprint Medicines : Appoints Habib Dable to its Board of Directors - Form 8-K
2022Blueprint Medicines Corp : Change in Directors or Principal Officers, Financial Statements..
2022Blueprint Medicines Appoints Habib Dable to its Board of Directors
2022Blueprint Medicines Appoints Habib Dable to its Board of Directors
2022Blueprint Medicines Shares Decline After Citigroup Downgrade
2022Blueprint Medicines Corp : Regulation FD Disclosure, Other Events, Financial Statements an..
2022Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of..
2022Blueprint Medicines Corporation Announces Updates on AYVAKIT/AYVAKYT
2022Insider Sell: Blueprint Medicines
2022Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022Insider Sell: Blueprint Medicines
2022Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022BLUEPRINT MEDICINES CORP Management's Discussion and Analysis of Financial Condition a..
2022Blueprint Medicines : Q1 Earnings Snapshot
2022Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q1 Revenue $62.7M, vs. St..
2022Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended Ma..
2022Blueprint Medicines Corporation Provides Revenue Guidance for the Year 2022
2022Blueprint Medicines Corp : Regulation FD Disclosure (form 8-K)
2022Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2..
2022SK Inc. - Biopharm Investment and Sister Company Sign Collaborations to Advance Promisi..
2022Blueprint Medicines Reports BLU-945 Trial Data
2022Blueprint Medicines Corp : Regulation FD Disclosure, Other Events, Financial Statements an..
2022Blueprint Medicines Corporation Announces Blu-945 Proof-Of-Concept Data Supporting Init..
2022Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022Blueprint Medicines Says European Commission Expands Indication for Ayvakyt to Advanced..
Prochain événement sur BLUEPRINT MEDICINES CORPORATION